Eli Lilly (LLY)
1,055.18
-2.71 (-0.26%)
NYSE · Last Trade: Dec 2nd, 1:42 PM EST
As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered army of retail investors. This evolving landscape is characterized by heightened volatility, new thematic rallies, and a significant blurring of
Via MarketMinute · December 2, 2025
The U.S. stock market is currently navigating a period of cautious optimism, working to regain solid ground after a tumultuous year marked by significant losses in early 2025 and persistent concerns about valuation. While major indices have shown remarkable resilience, underlying economic headwinds and the evolving landscape of artificial
Via MarketMinute · December 2, 2025
Via MarketBeat · December 1, 2025
Via Benzinga · December 1, 2025
Lee also cited the end of the Federal Reserve’s quantitative tightening program, effective December 1, as a tailwind for U.S. equity markets.
Via Stocktwits · December 1, 2025
Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect.
Via Stocktwits · December 1, 2025
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?
Via The Motley Fool · December 1, 2025
Eli Lilly recently gained a trillion-dollar valuation. S&P 500 titans Nvidia leads
Via Investor's Business Daily · December 1, 2025
The Vanguard Dividend Appreciation ETF is a popular choice among dividend investors.
Via The Motley Fool · December 1, 2025
The puzzle pieces are in place for the world's largest retailer by revenue to reach a milestone in 2026 that only a dozen public companies globally have achieved.
Via The Motley Fool · December 1, 2025
These stocks can be set-it-and-forget-it holdings for most investors.
Via The Motley Fool · November 30, 2025
This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon?
Via The Motley Fool · November 30, 2025
If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.
Via The Motley Fool · November 30, 2025
If you don't want to invest in individual growth stocks, these ETFs could be worth a second look.
Via The Motley Fool · November 29, 2025
Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.
Via The Motley Fool · November 29, 2025
Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.
Via The Motley Fool · November 29, 2025
These top growth stocks are worth a second look.
Via The Motley Fool · November 29, 2025
MarketBeat Week in Review – 11/24 - 11/28marketbeat.com
Via MarketBeat · November 29, 2025
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · November 28, 2025
The financial markets in late 2025 are signaling a significant, albeit cautious, shift away from the concentrated leadership that has defined much of the past two years. For an extended period, market gains were predominantly driven by a select cohort of mega-cap technology companies, often dubbed the "Magnificent Seven," largely
Via MarketMinute · November 28, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill · November 28, 2025
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · November 28, 2025
Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.
Via Barchart.com · November 28, 2025
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.
Via The Motley Fool · November 27, 2025
